Bioactivity | Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence[1]. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia[2]. |
Invitro | Lidocaine (100 μM, 200 μM, 28 天) 减慢 hPSC 细胞系的传导速度 (CV)[4]。Lidocaine (0.1-2000 μM, 5 分钟) 在 hiPSC 衍生的心肌细胞中表现出有限的使用依赖性阻滞(UDB) [5]。Lidocaine (30 μM) 使 LQTS 心肌细胞的 QT 间期降至正常水平[6]。 0 --> Lidocaine (GMP) 相关抗体: |
In Vivo | Lidocaine GMP (Lignocaine) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by Lidocaine GMP has slower onset and faster recovery compared with thermal nociception block[3]. |
Name | Lidocaine (GMP) |
CAS | 137-58-6 |
Formula | C14H22N2O |
Molar Mass | 234.34 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. Cummins TR, et al. Setting up for the block: the mechanism underlying lidocaine's use-dependent inhibition of sodium channels. J Physiol. 2007 Jul 1;582(Pt 1):11. [2]. Sui H, et al. Lidocaine inhibits growth, migration and invasion of gastric carcinoma cells by up-regulation of miR-145. BMC Cancer. 2019 Mar 15;19(1):233. [3]. Li Z, et al. Evaluation of the antinociceptive effects of lidocaine and bupivacaine on the tail nerves of healthy rats. Basic Clin Pharmacol Toxicol. 2013 Jul;113(1):31-6. [4]. Kadota S, et al. Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets. Eur Heart J. 2013 Apr;34(15):1147-56. [5]. Potet F, et al. GS-967 and Eleclazine Block Sodium Channels in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Mol Pharmacol. 2020 Nov;98(5):540-547. [6]. Wang F, et al. In Vitro Drug Screening Using iPSC-Derived Cardiomyocytes of a Long QT-Syndrome Patient Carrying KCNQ1 & TRPM4 Dual Mutation: An Experimental Personalized Treatment. Cells. 2022 Aug 11;11(16):2495. |